Overweight among children younger than 3 years in a low-income patient population: prevalence in 2010

Jessica M Robbins1, John V Nguyen2, Kevin L Houck2

  • 1Philadelphia Department of Public Health, Philadelphia, PA, USA jessica.robbins@phila.gov.

Clinical Pediatrics
|March 18, 2014
PubMed

Insights

Overweight and obesity affect 10-16% of young children, with "other/unknown" race and Hispanic girls showing higher risks. Early intervention is crucial for this growing public health concern.

Area of Science:

  • Pediatrics
  • Public Health
  • Childhood Obesity

Background:

  • Early childhood is a critical period for weight status development.
  • Overweight and obesity in very young children pose long-term health risks.
  • Accurate measurement of weight status in infants and toddlers is essential.

Purpose of the Study:

  • To determine the prevalence of overweight and obesity in children aged 0-2 years.
  • To identify factors associated with elevated weight status in early childhood.
  • To compare three common measures of weight status: weight-for-age, weight-for-length, and body mass index-for-age.

Main Methods:

  • Cross-sectional study design.
  • Data collected during well-child visits at Philadelphia Health Centers.
  • Analysis of weight status using weight-for-age, weight-for-length, and BMI-for-age.

Main Results:

  • 10-16% of boys and 10-13% of girls aged 0-2 years were classified as having high weight.
  • No clear link found between feeding method and weight status.
  • "Other/unknown" race was associated with higher overweight rates compared to African Americans.
  • Hispanic girls showed higher rates of high weight-for-age and weight-for-length than African American girls.

Conclusions:

  • A significant proportion of very young children exhibit elevated weight status.
  • Commonly used weight measures consistently identify high weight in this age group.
  • Urgent need for clinical strategies to prevent and manage overweight in infants and toddlers.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554